Balchem Corporation (BCPC) SEC Filings & Earnings Calls
EquiReason read 12 Balchem Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-10-23 — Record quarterly net sales ($290.7M, +8.6% YoY), net earnings ($46.7M, +16% YoY), and adjusted EBITDA ($80.3M, +12.4% YoY). All three segments grew sales and earnings. CEO cited 'h.
Source: SEC EDGAR filings · figures as of 2026-09-30 · read by EquiReason
BCPCBalchem CorporationFollow BCPC — free
—
Price chart with a free account
- Market cap
- 5.6B
- P/E TTM
- 33.3
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 18 Feb, in 117 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Oct 20268-K · 2.02Record quarterly net sales ($290.7M, +8.6% YoY), net earnings ($46.7M, +16% YoY), and adjusted EBITDA ($80.3M, +12.4% YoY). All three segments grew sales and earnings. CEO cited 'healthy growth' and 'excellent quarter.'earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2026 | $291M | +9% y/y |
| Net earnings · Q3-2026 | $47M | +16% y/y |
| Adjusted EBITDA · Q3-2026 | $80M | +12% y/y |
| Free cash flow · Q3-2026 | $58M | |
| Cash flows from operations · Q3-2026 | $70M | |
| Diluted net earnings per common share · Q3-2026 | $1.46 | +18% y/y |
| Adjusted net earnings per common share · Q3-2026 | $1.57 | +16% y/y |
| Human Nutrition and Health segment sales · Human Nutrition and Health · Q3-2026 | $188M | +8% y/y |
| Animal Nutrition and Health segment sales · Animal Nutrition and Health · Q3-2026 | $63M | +12% y/y |
| Specialty Products segment sales · Specialty Products · Q3-2026 | $37M | +5% y/y |
Risks flagged
No material risks disclosed; filing is positive earnings result with no forward guidance or risk factors
“No risk factors or negative commentary in the press release”
23 Oct 202610-QBalchem reported Q3 2026 revenue of $290.7M (+8.6% YoY) and net earnings of $46.7M (+16.0% YoY), with margin expansion across segments.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2026 | $291M | +9% y/y |
| Gross margin · Q3-2026 | 36.4% | |
| Operating margin · Q3-2026 | 21.5% | |
| Net earnings · Q3-2026 | $47M | +16% y/y |
| Human Nutrition & Health segment net sales · Human Nutrition & Health · Q3-2026 | $188M | +8% y/y |
| Animal Nutrition & Health segment net sales · Animal Nutrition & Health · Q3-2026 | $63M | +12% y/y |
| Specialty Products segment net sales · Specialty Products · Q3-2026 | $37M | +5% y/y |
| Human Nutrition & Health segment earnings from operations · Human Nutrition & Health · Q3-2026 | $46M | +12% y/y |
| Animal Nutrition & Health segment earnings from operations · Animal Nutrition & Health · Q3-2026 | $7M | +83% y/y |
| Specialty Products segment earnings from operations · Specialty Products · Q3-2026 | $12M | +7% y/y |
Risks flagged
Tariff uncertainty
“We do not expect the financial impacts of these developments to have a material effect on our future results of operations or cash flows.” · word for word
Impairment charge
“a non-cash impairment charge of $1,915 on certain manufacturing equipment that will not be placed into service” · word for word
31 Jul 202610-QBalchem reported Q2 2026 revenue of $284.0M (+11.2% YoY) and net earnings of $44.6M (+16.6% YoY), with all segments growing.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $284M | +11% y/y |
| Gross margin · Q2-2026 | 36.5% | |
| Operating margin · Q2-2026 | 20.9% | |
| Net earnings · Q2-2026 | $45M | +17% y/y |
| Human Nutrition & Health net sales · Human Nutrition & Health · Q2-2026 | $177M | +10% y/y |
| Animal Nutrition & Health net sales · Animal Nutrition & Health · Q2-2026 | $64M | +15% y/y |
| Specialty Products net sales · Specialty Products · Q2-2026 | $41M | +9% y/y |
| Human Nutrition & Health earnings from operations · Human Nutrition & Health · Q2-2026 | $42M | +11% y/y |
| Animal Nutrition & Health earnings from operations · Animal Nutrition & Health · Q2-2026 | $5M | +49% y/y |
| Specialty Products earnings from operations · Specialty Products · Q2-2026 | $13M | +14% y/y |
Risks flagged
Tariff uncertainty
“we do not expect them to have a material effect on our future results of operations or cash flows.” · word for word
Input cost inflation
“partially offset by certain higher manufacturing input costs” · word for word
31 Jul 20268-K · 2.02Record quarterly net sales ($284.0M, +11.2%), net earnings ($44.6M, +16.6%), and adjusted EBITDA ($77.9M, +12.6%). All three segments grew. Credit facility expanded to $650M, extended to 2031. $29M in stock repurchases in Q2.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $284M | +11% y/y |
| Net earnings · Q2-2026 | $45M | +17% y/y |
| Adjusted EBITDA · Q2-2026 | $78M | +13% y/y |
| Free cash flow · Q2-2026 | $36M | |
| Operating cash flow · Q2-2026 | $47M | |
| Diluted EPS · Q2-2026 | $1.39 | +19% y/y |
| Adjusted EPS · Q2-2026 | $1.49 | +17% y/y |
| Human Nutrition & Health segment sales · Human Nutrition & Health · Q2-2026 | $177M | +10% y/y |
| Animal Nutrition & Health segment sales · Animal Nutrition & Health · Q2-2026 | $65M | +15% y/y |
| Specialty Products segment sales · Specialty Products · Q2-2026 | $41M | +9% y/y |
Risks flagged
Manufacturing input cost pressures noted across all segments, partially offsetting sales growth.
“Partially offset by certain higher manufacturing input costs and higher operating expenses.” · word for word
27 Jul 20268-K · 1.01, 2.03Balchem amended its credit agreement, increasing revolving commitment from $550M to $650M, extending maturity to 2031, and reducing margins at certain leverage tiers.open
Figures in the filing · each found in the filing text
| Revolving commitment amount · corporate · point_in_time | $650M |
Risks flagged
Increased debt capacity could lead to higher leverage if used aggressively
“Facility increased by $100M; company has low leverage currently (Tier 1 pricing).”
30 Apr 202610-QNet sales $271M (+8% y/y); Gross margin $101M (+15% y/y); Earnings from operations $56M (+9% y/y)open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $271M | +8% y/y |
| Gross margin · Q1-2026 | $101M | +15% y/y |
| Earnings from operations · Q1-2026 | $56M | +9% y/y |
| Net earnings · Q1-2026 | $40M | +9% y/y |
| Operating margin · Q1-2026 | 20.5% | |
| Human Nutrition & Health segment net sales · Human Nutrition & Health · Q1-2026 | $172M | +8% y/y |
| Animal Nutrition & Health segment net sales · Animal Nutrition & Health · Q1-2026 | $62M | +9% y/y |
| Specialty Products segment net sales · Specialty Products · Q1-2026 | $35M | +4% y/y |
| Cash flows provided by operating activities · Q1-2026 | $40M | +10% y/y |
| Capital expenditures and intangible assets acquired · Q1-2026 | $6M | +13% y/y |
Risks flagged
Tariff uncertainty
“we do not expect them to have a material effect on our future results of operations or cash flows” · word for word
Raw material inflation
“partially offset by raw material inflation” · word for word
30 Apr 20268-K · 2.02Net sales $271M (+8% y/y); Adjusted EBITDA $74M (+12% y/y); Adjusted earnings per share $1.33 (+9% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $271M | +8% y/y |
| Adjusted EBITDA · Q1-2026 | $74M | +12% y/y |
| Adjusted earnings per share · Q1-2026 | $1.33 | +9% y/y |
| GAAP net earnings · Q1-2026 | $40M | +9% y/y |
| Free cash flow · Q1-2026 | $34M |
Risks flagged
Geopolitical and trade uncertainty could impact future performance.
“maneuver through the geopolitical environment and the changing global trade outlook that are impacting markets” · word for word
27 Apr 2026DEF 14ANet sales $1.04B (+9% y/y); Adjusted EBITDA $275M (+10% y/y); Adjusted net earnings $168M (+17% y/y)open
Figures in the filing · each found in the filing text
| Net sales · FY2025 | $1.04B | +9% y/y |
| Adjusted EBITDA · FY2025 | $275M | +10% y/y |
| Adjusted net earnings · FY2025 | $168M | +17% y/y |
| Adjusted diluted EPS · FY2025 | $5.15 | +18% y/y |
| Operating cash flow · FY2025 | $217M | |
| Free cash flow · FY2025 | $174M | |
| GAAP Net Earnings · FY2025 | $155M | |
| Dividend per share · FY2025 | $0.96 | +10% y/y |
| Net debt leverage ratio · FY2025 | $0.30 |
20 Feb 202610-KTotal Revenue $1.04B (+9% y/y); Gross Margin $371M (+10% y/y); Operating Margin 20.2; Guidance: Capex guided $40-45M for 2026open
Figures in the filing · each found in the filing text
| Total Revenue · FY2025 | $1.04B | +9% y/y |
| Gross Margin · FY2025 | $371M | +10% y/y |
| Operating Margin · FY2025 | 20.2% | |
| Operating Cash Flow · FY2025 | $217M | +19% y/y |
| Capital Expenditures · FY2025 | $43M | +22% y/y |
| Human Nutrition & Health Revenue · Human Nutrition and Health · FY2025 | $659M | +10% y/y |
| Animal Nutrition & Health Revenue · Animal Nutrition and Health · FY2025 | $231M | +8% y/y |
| Specialty Products Revenue · Specialty Products · FY2025 | $141M | +6% y/y |
Guidance
Capex guided $40-45M for 2026
Management expects operations to generate sufficient cash flow; capex guided higher to support growth.
Risks flagged
Ethylene Oxide Regulatory Risk
“Any future determination by the EPA to discontinue permitted use of ethylene oxide or propylene oxide would have a material adverse effect on our business and financial results.” · word for word
Raw Material Price Volatility
“The principal raw materials that we use in the manufacture of our products can be subject to price fluctuations due to market conditions and factors beyond our control.” · word for word
Supply Chain Disruption
“National and international conflicts such as war, border closures, civil disturbances and terrorist acts... may increase the likelihood of already strained supply interruptions.” · word for word
20 Feb 20268-K · 2.02Net sales $1.04B (+9% y/y); Adjusted EBITDA $275M (+10% y/y); Adjusted earnings per share $5.15 (+18% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net sales · FY2025 | $1.04B | +9% y/y |
| Adjusted EBITDA · FY2025 | $275M | +10% y/y |
| Adjusted earnings per share · FY2025 | $5.15 | +18% y/y |
| GAAP net earnings · FY2025 | $155M | +21% y/y |
| Free cash flow · FY2025 | $174M | |
| Q4 Net sales · Q4-2025 | $264M | +10% y/y |
| Q4 Adjusted EBITDA · Q4-2025 | $68M | +8% y/y |
19 Feb 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportSEC ↗
10 Dec 20258-K · 7.01Dividend per share $0.96 (+10% y/y)open
Figures in the filing · each found in the filing text
| dividend per share · Q4-2025 | $0.96 | +10% y/y |
Balchem Corporation — questions
- What did Balchem Corporation file recently?
- 12 SEC filings in the last 12 months. Latest: 8-K on 2026-10-23 — Record quarterly net sales ($290.7M, +8.6% YoY), net earnings ($46.7M, +16% YoY), and adjusted EBITDA ($80.3M, +12.4% YoY). All three segments grew sales and earnings. CEO cited 'healthy growth' and 'excellent quarter.'
Every figure on this page comes from Balchem Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.